PFE
PFE — Healthcare
Graham: 12
Buffett: 60
Lynch: 29
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.
Price ?
27.28
Market Cap ?
155.2B
P/E ?
20.06
P/B ?
1.79
Div Yield ?
6.30%
52W Range ?
20.92 - 27.94
200W MA ?
28.59
12
Graham-style buying rate (0-100)
Criteria breakdown
- ✓ Company size sufficient (large-cap) ? $155,178,369,024 — Uses market cap >= $2B as proxy
- ✗ Solid financial condition (CR>=2; LT debt <= NCAV) ? CR=1.16 | D/E=0.78 — Partial: checks current ratio; LT debt vs NCAV unavailable
- ✓ Uninterrupted dividends for 20 years ?
- ✓ No losses in last 10 years ? 10y window — Positive earnings for last 17y
- ✗ EPS growth >= 33% over 10 years ? ~16%
- ✗ Price-to-Book (P/B) <= 1.5 ? 1.79
- ✗ Price-to-Earnings (P/E) <= 15 ? 20.1 — Uses trailing P/E as proxy for 3y avg EPS
- ✗ Combined formula (P/E * P/B) <= 22.5 ? 36.0
- ✗ Margin of safety >= 20% ? -34% — Intrinsic = EPS * 15
- ✗ High ROE maintained without excessive debt ? ROE=8.9% | D/E=0.78 — Approximate threshold ROE = 15%, D/E = 1.0
What is evaluated (Graham):
- Valuation discipline and buying below intrinsic value.
- Financial resilience: liquidity and prudent leverage.
- Consistent dividends and earnings over long horizons.
"The intelligent investor is a realist who sells to optimists and buys from pessimists." — Benjamin Graham
60
Buffett-style buying rate (0-100)
Criteria breakdown
- ✗ Positive and growing FCF (multi-year) ? 15,653,000,000 -> 14,333,000,000
- ✓ ROIC >= 12% sustained ? 21.5%
- ✗ High ROE (proxy for durable advantages) ? 8.9% — Consistency over years not checked
- ✓ Net profit margin >= 10% ? 12.4% — Derived from available financial filings
- ✓ Conservative leverage (D/E <= 1.0) ? 0.78
- ✓ Sustainable shareholder returns (dividend > 0%) ? 6.30% — Does not assess buybacks or payout safety
What is evaluated (Buffett):
- Durable advantages: high ROE, healthy margins.
- Balance discipline and shareholder friendly capital use.
- Positive free cash flow and efficient reinvestment.
"It is far better to buy a wonderful company at a fair price than a fair company at a wonderful price." — Warren Buffett
29
Lynch-style buying rate (0-100)
Criteria breakdown
- ? PEG ratio (P/E / growth) <= 1.0 ? — needs positive EPS growth
- ✗ Positive multi-year EPS growth (per-year >= 10%) ? ~-22.9%/yr
- ✗ Conservative leverage (D/E <= 0.5) ? 0.78
- ✓ Sustainable profitability (net margin >= 5%) ? 12.4%
- ✓ Earnings stability (no losses in 10y) ? 10y window
What is evaluated (Lynch):
- Growth at a reasonable price (PEG and EPS CAGR).
- Durable earnings with limited drawdowns.
- Conservative balance sheet and baseline profitability.
"Know what you own, and know why you own it." — Peter Lynch